Discover how Baysient’s T3 application supports precision dosing for Vedolizumab IV therapy. In this video, we walk through a case involving an 80 kg patient, showing how T3 leverages patient-specific data to recommend optimal dosing intervals and achieve therapeutic goals.
Key highlights include:
✔ Generating individualized dosing recommendations based on patient-specific metrics.
✔ Understanding how dosing intervals impact trough concentrations and overall treatment outcomes.
✔ Utilizing probability charts to evaluate antibody risk and remission likelihood.
Watch to see how T3 empowers providers to move beyond standard dosing regimens, providing personalized care that enhances patient outcomes and treatment durability.
#ibs #medication #pharmacology
About Baysient:
Baysient develops SaaS, cloud-based software that provides medical providers with a full line of individual dosage-determination products for both small-molecule drugs and biologics to facilitate individualized and improved treatment outcomes for inflammatory diseases such as IBD, RA, etc. Baysient’s software uses Bayesian models, routine lab results, and demographic information to allow physicians to individualize dosing to a specific target trough level.
